Category: Money Tips Date: 2006-09-24
Or to speed up the integration process
We will report the depth of the subsequent more detailed analysis of the company's situation, including specific profit forecasts, follow-up possible effects of the integration of the company and our current research in Guangdong Tempe, so stay tuned.
(1) on the road of growth of real medicine: from textiles to medicine changes. We are right on the real history of the development of Chinese medicine was in order, sought to clarify its development for investors over the years.
(2) The company has a wealth of medical assets. Pharmaceutical company's existing assets, mainly in the chemical pharmaceutical, biopharmaceutical and medical device fields. The existing assets, we recommend investors to focus on ordinary shares and the Guangdong Pharmaceutical Tempe.
(3) Guangdong Temple are currently being marketed to Ulinastatin mainly a class of drugs the country with the outbreak of the potential of Kai Li Kang.
(4) The company's most important source of profit remains a Lianhua Supermarket return on investment.
(5) The company's future development strategy of the group's assets, an integrated platform for medicine.
(6) earnings forecasts and investment advice. Accordance with the terms of existing assets, our initial prediction on the performance of the 2006-2008 real medicine were 0.32 yuan, 0.36 yuan and 0.42 yuan (do not rule out the report in depth may be adjusted). Corresponding to yesterday's closing price (10.74 yuan), predicted price-earnings ratio of 33.56 times, respectively, 29.83 percent and 25.57-fold, in the current price that has some support. Taking into account the strategic position of the future of real medicine, real medicine, we raise the rating to "buy."
(7) major uncertainties. The integration process will take time, and its process and the specific ways there may be uncertainties, we hope that investors will form a rational expectations. For investment holding companies to track performance more difficult.
